0001437749-17-010852.txt : 20170607 0001437749-17-010852.hdr.sgml : 20170607 20170607131045 ACCESSION NUMBER: 0001437749-17-010852 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170607 DATE AS OF CHANGE: 20170607 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MDC HOLDINGS INC CENTRAL INDEX KEY: 0000773141 STANDARD INDUSTRIAL CLASSIFICATION: OPERATIVE BUILDERS [1531] IRS NUMBER: 840622967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-36619 FILM NUMBER: 17896733 BUSINESS ADDRESS: STREET 1: 4350 S MONACO STREET STREET 2: SUITE 500 CITY: DENVER STATE: CO ZIP: 80237 BUSINESS PHONE: 3037731100 MAIL ADDRESS: STREET 1: 4350 S MONACO STREET STREET 2: SUITE 500 CITY: DENVER STATE: CO ZIP: 80237 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MANDARICH DAVID D CENTRAL INDEX KEY: 0001009874 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 4350 S. MONACO STREET, SUITE 500 CITY: DENVER STATE: CO ZIP: 80237 SC 13D/A 1 mand20170606_sc13da.htm SCHEDULE 13D/A mand20170606_sc13da.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 23)*

 

M.D.C. HOLDINGS, INC.

(Name of Issuer)

 

Common Stock, $0.01 Per Share

(Title of Class of Securities)

 

552676 108

(CUSIP Number)

 

David D. Mandarich, 4350 S. Monaco St., Suite 500, Denver, CO 80237

(303) 773-1100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

June 6, 2017

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1 (e), 13d-1(f) or 13d-1(g), check the following box [ ].

 

*

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
Page 1 of 6

 

 

 

 

CUSIP NO. 552676 108

 

(1)

NAME OF REPORTING PERSON

 
 

David D. Mandarich

 
     

(2)

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) [ ]

 

Not Applicable

(b) [ ]

     

(3)

SEC USE ONLY

 
     

(4)

SOURCE OF FUNDS

 
 

OO

 
     

(5)

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2 (e)

[ ]
  Not Applicable  
     

(6)

CITIZENSHIP OR PLACE OF ORGANIZATION

 
 

United States of America

 
     
    (7) SOLE VOTING POWER  
      5,592,551  

Number of

     

Shares

(8) SHARED VOTING POWER  

Beneficially

  0  

Owned by

     

Each

(9) SOLE DISPOSITIVE POWER  

Reporting

  5,592,551  

Person with

     
    (10) SHARED DISPOSITIVE POWER  
    0  
       

(11)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 
  5,592,551  
     

(12)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

[ ]
 

Not Applicable

 
     

(13)

PERCENT OF CLASS REPRESENTED BY THE AMOUNT IN ROW (11)

 
 

10.4%

 
     

(14)

TYPE OF REPORTING PERSON

 
 

IN

 
     

 

 
Page 2 of 6

 

 


 

EXPLANATORY NOTE: On June 6, 2017, an option granted to reporting person on May 18, 2015 immediately vested with respect to 1,050,000 shares in that the Common Stock as reported on the New York Stock Exchange in 20 out of 30 consecutive trading days closed at a price equal to or greater than 120% of the closing price of the option date of grant.

 


 

The Reporting Person, David D. Mandarich, hereby amends his Schedule 13D relating to Common Stock, par value $0.01, of M.D.C. Holdings, Inc. (the “Company”).

 

Item 1.

Security and Issuer.

 

This statement on Schedule 13D (this “Statement”) relates to the Common Stock of the Company. The address of the principal executive office of the Company is 4350 South Monaco Street, Suite 500, Denver, Colorado 80237.

 

Item 2.

Identity and Background.

 

 

(a)

This Statement is being filed by David D. Mandarich.

 

 

(b)

Mr. Mandarich’s principal place of business is M.D.C. Holdings, Inc., 4350 South Monaco Street, Suite 500, Denver, Colorado 80237.

 

 

(c)

Mr. Mandarich’s principal occupation is President and Chief Operating Officer of the Company.

 

 

(d)

During the last five years, Mr. Mandarich has not been convicted in a criminal proceeding.

 

 

(e)

During the last five years, Mr. Mandarich has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

 

(f)

Mr. Mandarich is a citizen of the United States.

 

Item 3.

Source and Amount of Funds or Other Consideration.

 

Of the shares of Common Stock that Mr. Mandarich acquired beneficial ownership in the twelve months preceding the date of this Statement, he beneficially acquired: (i) 32,200 shares of restricted stock awarded on February 2, 2017 for no cash consideration in connection with his service as the Company’s President and Chief Operating Officer and (ii) 1,050,000 shares that he has the right to acquire under an option, granted May 18, 2015 in connection with his service as the Company’s President and Chief Operating Officer, which immediately vested on June 6, 2017 in that the Common Stock as reported on the New York Stock Exchange in 20 out of 30 consecutive trading days closed at a price equal to or greater than 120% of the closing price of the option date of grant.

 

Item 4.

Purpose of Transaction.

 

All of the securities reported herein were acquired for investment purposes and/or as compensation for, and in connection with, Mr. Mandarich’s positions with the Company.

 

 

 
Page 3 of 6

 

 

Mr. Mandarich is the President and Chief Operating Officer of the Company. In these capacities, Mr. Mandarich takes, and will continue to take, an active role in the Company’s management and strategic direction. Additionally, in his capacity as a shareholder of the Company, Mr. Mandarich reviews and intends to continue to review, on an ongoing basis, his investment in the Company. Depending on the factors discussed below and subject to applicable law and the policies of the Company, Mr. Mandarich may from time to time acquire additional securities of the Company or otherwise dispose of some or all of his securities of the Company. Any transactions that Mr. Mandarich may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Company, the financial condition, results of operations and prospects of the Company, general economic, financial market and industry conditions, other investment and business opportunities available to Mr. Mandarich, tax and estate planning considerations and other factors.

 

Other than as described above in this Item 4, Mr. Mandarich has no present plan or proposal relating to or that would result in any of the transactions or changes listed in Items 4(a) through 4(j) of Schedule 13D. However, as part of the ongoing evaluation of this investment and investment alternatives, Mr. Mandarich may consider such matters and, subject to applicable law and the policies of the Company, may formulate a plan with respect to such matters and, from time to time, may hold discussions with or make proposals to management or the Board of Directors of the Company, other shareholders of the Company or other third parties regarding such matters.

 

Item 5.

Interest in Securities of the Issuer

 

 

(a)

Mr. Mandarich beneficially owns an aggregate of 5,592,551 shares of Common Stock, representing approximately 10.4% of the outstanding Common Stock of the Company. The ownership percentage set forth above is based upon 51,561,322 shares of Common Stock of the Company outstanding, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, plus an additional 2,331,000 shares which Mr. Mandarich has the right to acquire upon the exercise of stock options that are fully vested.

 

 

(b)

Mr. Mandarich has the:

 

 

(i)

Sole power to vote or direct the vote of 5,592,551 shares. This consists of 3,174,423 shares that he directly owns, 2,331,000 shares issuable upon the exercise of stock options granted under the Company's equity incentive plans, 82,850 shares of restricted stock granted under the Issuer's Equity Incentive Plans, and 4,278 unitized shares held in a stock fund in the Company’s 401(k) Savings Plan, which changes on a daily basis.

 

 

(ii)

Shared power to vote or direct the vote of -0- shares.

 

 

(iii)

Sole power to dispose or direct the disposition of 5,592,551 shares. This consists of the shares described in response to Item 5(b)(i) above.

 

 

(iv)

Shared power to dispose or direct the disposition of -0- shares.

 

 

(c)

Other than the vesting of an option with respect to 1,050,000 shares of Common Stock as described in Item 3 above, Mr. Mandarich has had no transactions in the Company’s securities during the past sixty days.

 

 

(d)

None.

 

 

 
Page 4 of 6

 

 

 

(e)

Not applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Not applicable.

 

Item 7.

Material to be Filed as Exhibits.

 

None.

 


 

 
Page 5 of 6

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:

June 7, 2017

 

 

Signature:

/s/ David D. Mandarich          

 

 

Name:

David D. Mandarich

 

 

Page 6 of 6